Sonntag, 28. April 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Rekrutierend

NCT-Nummer:
NCT05882058

Studienbeginn:
September 2023

Letztes Update:
26.03.2024

Wirkstoff:
BI 764532, formulation 1, BI 764532, formulation 2

Indikation (Clinical Trials):
Carcinoma, Small Cell Lung Carcinoma, Neuroendocrine Tumors

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Boehringer Ingelheim

Collaborator:
-

Kontakt

Studienlocations
(3 von 48)

Universitätsklinikum Carl Gustav Carus Dresden
01307 Dresden
(Sachsen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Boehringer Ingelheim
Phone: 08007234742
E-Mail: deutschland@bitrialsupport.com» Ansprechpartner anzeigen
Hautkrebszentrum Universitätsklinikum Erlangen
Ulmenweg 18
91054 Erlangen
(Bayern)
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Boehringer Ingelheim
Phone: 08007234742
E-Mail: deutschland@bitrialsupport.com» Ansprechpartner anzeigen
LungenClinic Grosshansdorf GmbH
22927 Großhansdorf
(Schleswig-Holstein)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Boehringer Ingelheim
Phone: 08007234742
E-Mail: deutschland@bitrialsupport.com» Ansprechpartner anzeigen
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
55131 Mainz
(Rheinland-Pfalz)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Boehringer Ingelheim
Phone: 08007234742
E-Mail: deutschland@bitrialsupport.com» Ansprechpartner anzeigen
University of California San Francisco
94143 San Francisco
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Boehringer Ingelheim
Phone: 833-602-2368
E-Mail: unitedstates@bitrialsupport.com» Ansprechpartner anzeigen
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
10016 New York
United StatesRekrutierend» Google-Maps
Ansprechpartner:
Boehringer Ingelheim
Phone: 833-602-2368
E-Mail: unitedstates@bitrialsupport.com» Ansprechpartner anzeigen
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
310016 Hangzhou
ChinaRekrutierend» Google-Maps
Ansprechpartner:
Boehringer Ingelheim
Phone: 4001200553
E-Mail: china@bitrialsupport.com» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Brief Summary:

This study is open to adults with small cell lung cancer and other neuroendocrine tumours.

The study is in people with advanced cancer for whom previous treatment was not successful or

no standard treatment exists.

The purpose of this study is to find a suitable dose of BI 764532 that people with advanced

cancer can tolerate when taken alone. 2 different doses of BI 764532 are tested in this

study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an

antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer.

Participants are put into 2 groups randomly, which means by chance. One group gets dose 1 of

BI 764532 and the other group gets dose 2 of BI 764532. Participants get BI 764532 infusions

into a vein when starting treatment. If there is benefit for the participants and if they can

tolerate it, the treatment is given up to the maximum duration of the study. During this

time, participants visit the study site regularly. The total number of visits depends on how

they respond to and tolerate the treatment. The first study visits include an over-night stay

to monitor participants' safety. Doctors record any unwanted effects and regularly check the

general health of the participants.

Ein-/Ausschlusskriterien

Inclusion criteria:

1. Male or female participants ≥18 years old and at least at the legal age of consent in

countries where it is greater than 18 years at the time of signature of the informed

consent form (ICF).

2. Signed and dated written informed consent in accordance with International Council for

Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to

admission to the trial.

3. Histologically or cytologically confirmed, cancer of the following histologies:

- Small cell lung cancer (SCLC)

- Extra-pulmonary neuroendocrine carcinoma (epNEC) (except Merkel cell carcinoma

(MCC), Medullary thyroid cancer (MTC) and Neuroendocrine prostate cancer (NEPC))

- Large cell neuroendocrine carcinoma (LCNEC) of the lung Patients with tumours

with mixed histologies for any above type are eligible only if the neuroendocrine

carcinoma/small tumour cells component is predominant and represents at least 50%

of the overall tumour tissue.

Patients must have progressed or recurred after standard of care therapy

- SCLC: after at least two prior lines of therapy, including at least one

platinum-based regimen; in countries where standard of care in first line therapy

includes PD-L1 inhibitor treatment patients should have received the combination

of platinum-based regimen plus PD-L1 inhibitor unless they have been unable to

receive checkpoint inhibitor treatment.

- epNEC/LCNEC: after at least one platinum-based regimen

4. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.

5. Measurable lesions as defined per Response Evaluation Criteria In Solid Tumours

(RECIST) v 1.1 within 21 days prior to the first dose of BI 764532.

6. Availability of archival tumour tissue sample.

7. Adequate organ function as defined in the protocol.

8. All toxicities related to previous anti-cancer therapies have resolved = Common

Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment

administration (except for alopecia, peripheral neuropathy, fatigue and

endocrinopathies controlled by replacement therapy which must be = CTCAE Grade 2 and

amenorrhea/menstrual disorders which can be any grade).

9. Women of childbearing potential (WOCBP)and men able to father a child must be ready

and able to use highly effective methods of birth control per ICH M3 (R2) that result

in a low failure rate of less than 1% per year when used consistently and correctly. A

list of contraception methods meeting these criteria and instructions on the duration

of their use is provided in the participant information

Exclusion criteria:

1. Untreated or symptomatic brain metastases. Participants with treated, stable brain

metastases are eligible provided they meet the following criteria:

- Radiotherapy or surgery for brain metastases was completed at least 2 weeks prior

to the first administration of BI 764532.

- Patient is off steroids for at least 7 days (physiologic doses of steroids are

permitted), and the patient is off anti-epileptic drugs for at least 7 days or on

stable doses of anti-epileptic drugs for malignant central nervous system (CNS)

disease.

2. Presence of leptomeningeal disease.

3. Active/previous history of interstitial lung disease or non-infectious pneumonitis

(any grade).

4. Participants who experienced severe, life-threatening immune-mediated adverse events

or infusion-related reactions including those that lead to permanent discontinuation

while on treatment with immuno-oncology agents.

5. Prior anti-cancer therapy:

- Patients who have been treated with any other anti-cancer drug within 4 weeks or

within 5 half-life periods (whichever is shorter) prior to first administration

of BI 764532.

- Patients who have been treated with extensive field radiotherapy including whole

brain irradiation within 2 weeks prior to first administration of BI 764532.

6. Previous treatment with Delta-like ligand 3 (DLL3)-targeting T cell engagers or cell

therapies.

7. Diagnosis of immunodeficiency or systemic steroid therapy or any other form of

immunosuppressive therapy within 7 days prior to the first dose of BI 764532.

Physiological replacement of steroids is allowed.

8. Unresolved toxicity from prior anti-tumour therapy, defined as per protocol. Further

exclusion criteria apply.

Studien-Rationale

Primary outcome:

1. Objective response (OR), defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) (Time Frame - up to 23 months):
according to RECIST v 1.1 by investigator assessment from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.

2. Occurrence of treatment-emergent adverse events (TEAEs) during the on-treatment period (Time Frame - up to 23 months)

Secondary outcome:

1. Duration of objective response (DOR) based on investigator assessment (Time Frame - up to 23 months):
DOR is defined as the time from first documented confirmed OR until the earliest date of disease progression or death among patients with confirmed OR.

2. Progression-free survival (PFS) based on investigator assessment (Time Frame - up to 23 months):
PFS is defined as the time from treatment start until the earliest date of tumour progression according RECIST v 1.1 or death from any cause, whichever occurs first.

3. Disease control (DC), defined as best overall response of CR or PR or stable disease (SD) based on investigator assessment (Time Frame - up to 23 months):
where best overall response is defined according to RECIST v 1.1, from first treatment administration until the earliest of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent

4. Overall survival (OS), defined as the time from treatment start until death from any cause (Time Frame - up to 23 months)

5. Change from baseline in EORTC QLQ-C30 physical functioning domain score (Time Frame - at baseline, at month 23):
European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) The QLQ-C30 is comprised of 30 questions. It incorporates both multi-item scales and single-item measures. These include one global health status/Quality of Life (QoL) scale, five functional scales, three symptom scales and six single items to assess dyspnea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties. All scales and single-item measures range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems.

6. Change from baseline in EORTC QLQ-C30 role functioning domain score (Time Frame - at baseline, at month 23)

7. Occurrence of treatment-emergent AEs leading to study drug discontinuation during the on-treatment period (Time Frame - up to 23 months)

Studien-Arme

  • Experimental: Dose group 1
  • Experimental: Dose group 2

Geprüfte Regime

  • BI 764532, formulation 1:
    BI 764532, formulation 1
  • BI 764532, formulation 2:
    BI 764532, formulation 2

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.